Loading...
Market
What will be HilleVax's market cap status by the end of 2024?
2
Resolution / Starting Odds
Below $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
Above $1 billion • 25%
Publicly available financial data
Story
HilleVax Shares Plunge 88.6% to $1.60 After Norovirus Vaccine Fails in Mid-Stage Trial
Jul 8, 2024, 01:50 PM
HilleVax reported that its NEST-IN1 Phase 2b clinical study of HIL-214 in infants did not meet its primary or secondary efficacy endpoints. As a result, the company will discontinue further development of HIL-214 in infants. Following this announcement, HilleVax's stock plummeted, dropping 88.6% to $1.60 in premarket trade, with an 86.3% decline premarket. The failed trial aimed to prevent gastroenteritis caused by norovirus, specifically acute gastroenteritis. The significant decline in stock value reflects investor disappointment in the biotech company's sole clinical candidate's failure.
View original story
Similar markets
Below $10 billion • 25%
$10 billion - $15 billion • 25%
$15 billion - $20 billion • 25%
Above $20 billion • 25%
Below $3 billion • 25%
$3 billion to $5 billion • 25%
$5 billion to $7 billion • 25%
Above $7 billion • 25%
Top 10 • 25%
Top 20 • 25%
Top 50 • 25%
Below Top 50 • 25%
Less than $150 billion • 25%
$150 billion to $170 billion • 25%
$170 billion to $190 billion • 25%
More than $190 billion • 25%
<10% • 25%
10-20% • 25%
20-30% • 25%
>30% • 25%
<$300 million • 25%
$300-500 million • 25%
$500-700 million • 25%
>$700 million • 25%
Less than €5 billion • 25%
€5 billion to €6 billion • 25%
€6 billion to €7 billion • 25%
More than €7 billion • 25%
Below $15 billion • 25%
$15-$19.99 billion • 25%
$20-$24.99 billion • 25%
$25 billion or above • 25%